Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Zenas BioPharma Inc has a consensus price target of $39.44 based on the ratings of 9 analysts. The high is $55 issued by Evercore ISI Group on November 26, 2025. The low is $19 issued by Wolfe Research on February 4, 2025. The 3 most-recent analyst ratings were released by Evercore ISI Group, Morgan Stanley, and Citigroup on November 26, 2025, November 13, 2025, and October 28, 2025, respectively. With an average price target of $46 between Evercore ISI Group, Morgan Stanley, and Citigroup, there's an implied 45.99% upside for Zenas BioPharma Inc from these most-recent analyst ratings.
1calculated from analyst ratings
| Get Alert | |||||
|---|---|---|---|---|---|
| Nov 26, 2025 | 74.55% | 55 | Previous Initiates Current Outperform | Get Alert | |
| Nov 13, 2025 | 17.42% | 3437 | Previous Overweight Current Overweight | Get Alert | |
| Oct 28, 2025 | 45.99% | 2746 | Previous Buy Current Buy | Get Alert | |
| Oct 28, 2025 | 7.9% | 3134 | Previous Overweight Current Overweight | Get Alert | |
| Oct 28, 2025 | 39.64% | 3044 | Previous Buy Current Buy | Get Alert | |
| Oct 9, 2025 | 26.94% | 3540 | Previous Outperform Current Outperform | Get Alert | |
| Oct 9, 2025 | -4.79% | 3030 | Previous Buy Current Buy | Get Alert | |
| May 16, 2025 | -4.79% | 3030 | Previous Buy Current Buy | Get Alert | |
| Mar 20, 2025 | 11.08% | 35 | Previous Initiates Current Outperform | Get Alert | |
| Mar 12, 2025 | 42.81% | 4545 | Previous Buy Current Buy | Get Alert | |
| Mar 12, 2025 | -4.79% | 3030 | Previous Buy Current Buy | Get Alert | |
| Feb 4, 2025 | -39.7% | 19 | Previous Initiates Current Outperform | Get Alert | |
| Dec 16, 2024 | -4.79% | 30 | Previous Initiates Current Buy | Get Alert | |
| Dec 11, 2024 | 11.08% | 3540 | Previous Overweight Current Overweight | Get Alert | |
| Dec 3, 2024 | — | — | Previous Current Buy | Get Alert | |
| Oct 8, 2024 | -14.31% | 27 | Previous Initiates Current Buy | Get Alert | |
| Oct 8, 2024 | 11.08% | 35 | Previous Initiates Current Buy | Get Alert | |
| Oct 8, 2024 | 26.94% | 40 | Previous Initiates Current Overweight | Get Alert | |
| Oct 8, 2024 | 42.81% | 45 | Previous Initiates Current Buy | Get Alert |
The latest price target for Zenas BioPharma (NASDAQ:ZBIO) was reported by Evercore ISI Group on November 26, 2025. The analyst firm set a price target for $55.00 expecting ZBIO to rise to within 12 months (a possible 74.55% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Zenas BioPharma (NASDAQ:ZBIO) was provided by Evercore ISI Group, and Zenas BioPharma initiated their outperform rating.
There is no last upgrade for Zenas BioPharma
There is no last downgrade for Zenas BioPharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zenas BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zenas BioPharma was filed on November 26, 2025 so you should expect the next rating to be made available sometime around November 26, 2026.
While ratings are subjective and will change, the latest Zenas BioPharma (ZBIO) rating was a initiated with a price target of $0.00 to $55.00. The current price Zenas BioPharma (ZBIO) is trading at is $31.51, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.